Skip to main content

Table 1 Patients’ characteristics before and after propensity score matching (PSM)

From: Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis

Characteristic

Before PSM

After PSM

All

n = 227 (%)

Double-agent

n = 91 (%)

Triple-agent

n = 136 (%)

p-value

All

n = 140 (%)

Double-agent

n = 70 (%)

Triple-agent

n = 70 (%)

p-value

Sex

 Male

173 (76.2)

68 (74.7)

105 (77.2)

0.786

107 (76.4)

53 (75.7)

54 (77.1)

1

 Female

54 (23.8)

23 (25.3)

31 (22.8)

33 (23.6)

17 (24.3)

16 (22.9)

Age

59 [50,64]

60 [50,64]

59 [49,64]

0.398

59[49, 64.25]

59.5 [52.25, 64]

56 [48.25, 66]

0.347

  ≤ 60 years

124 (93.8)

48 (92.3)

76 (94.9)

0.684

78 (55.7)

38 (54.3)

40 (57.1)

0.865

  > 60 years

103 (6.2)

43 (7.7)

60 (5.1)

62 (44.3)

32 (45.7)

30 (42.9)

Diabetes mellitus

 Yes

16 (7)

5 (5.5)

11 (8.1)

0.485

12 (7.9)

5 (6.7)

7 (9.1)

0.57

 No

211 (93)

86 (94.5)

125 (91.9)

140 (92.1)

70 (93.3)

70 (90.9)

Location

 Upper

87 (38.3)

28 (30.8)

59 (43.4)

0.121

50 (35.7)

25 (35.7)

25 (35.7)

1

 Middle

49 (21.6)

20 (22.0)

29 (21.3)

34 (24.3)

17 (24.3)

17 (24.3)

 Lower

91 (40.1)

43 (47.3)

48 (35.3)

56 (40.0)

28 (40.0)

28 (40.0)

Differentiation of adenocarcinoma

 Well

7 (3.1)

3 (3.3)

4 (2.9)

0.981

–

–

–

1

 Moderately

66 (29.1)

26 (28.6)

40 (29.4)

39 (27.9)

20 (28.6)

19 (27.1)

 Poorly

154 (67.8)

62 (68.1)

92 (67.6)

101 (72.1)

50 (71.4)

51 (72.9)

Clinical T stage

 T2

4 (1.8)

2 (2.2)

2 (1.5)

0.512

2 (1.4)

1 (1.4)

1 (1.4)

0.998

 T3

141 (62.1)

61 (67.0)

80 (58.8)

87 (62.1)

43 (61.4)

44 (62.9)

 T4a

55 (24.2)

20 (22.0)

35 (25.7)

35 (25.0)

18 (25.7)

17 (24.3)

 T4b

27 (11.9)

8 (8.8)

19 (14.0)

16 (11.4)

8 (11.4)

8 (11.4)

Clinical N stage

 N0

2 (0.9)

2 (2.2)

0 (0.0)

< 0.001

–

–

–

0.983

 N1

81 (35.7)

48 (52.7)

33 (24.3)

61 (43.6)

31 (44.3)

30 (42.9)

 N2

97 (42.7)

29 (31.9)

68 (50.0)

55 (39.3)

27 (38.6)

28 (40.0)

 N3

47 (20.7)

12 (13.2)

35 (25.7)

24 (17.1)

12 (17.1)

12 (17.1)

Clinical stage groupings

 IIA

4 (1.8)

2 (2.2)

2 (1.5)

0.22

2 (1.4)

1 (1.4)

1 (1.4)

1

 IIB

2 (0.9)

2 (2.2)

0 (0.0)

–

–

–

 III

194 (85.5)

79 (86.8)

115 (84.6)

122 (87.1)

61 (87.1)

61 (87.1)

 IVA

27 (11.9)

8 (8.8)

19 (14.0)

16 (11.4)

8 (11.4)

8 (11.4)

Regimen

 FOLFOX6

8 (3.5)

8 (8.8)

–

 

4 (3.5)

4 (5.7)

–

 

 CAPOX

12 (5.3)

12 (13.2)

–

 

7 (5.3)

7 (10.0)

–

 

 SOX

71 (31.3)

71 (78.0)

–

–

59 (31.3)

59 (84.3)

–

–

 DCF

5 (2.2)

–

5 (3.7)

 

4 (2.2)

–

4 (5.7)

 

 FLOT

131 (57.7)

–

131 (96.3)

 

66 (57.7)

–

66 (94.3)

 

Cycles

4.00[4.00,4.00]

4.00[3.00,4.00]

4.00[4.00,5.00]

< 0.001

4.00[4.00,4.00]

4.00[3.00,4.00]

4.00[4.00,5.00]

0.006